|
News For JNJ;BCR;A;NUVA;COV;AFFX;STJ;EW;BAX;SYK;JNJ;BCR;A;NUVA;COV;AFFX;STJ;EW;BAX;SYK From The Last 14 Days Check below for free stories on JNJ;BCR;A;NUVA;COV;AFFX;STJ;EW;BAX;SYK;JNJ;BCR;A;NUVA;COV;AFFX;STJ;EW;BAX;SYK the last two weeks. |
|
|
| May 24, 2013 |
| 07:54 EDT |  | JNJ | Johnson & Johnson drug business should maintain momentum, says Wells Fargo
After attending J&J's bi-annual pharmaceutical business review, Wells Fargo believes that the revenue generated by four of the company's new drugs could double from 2012 to 2015. The firm thinks the company's pharmaceutical unit has one of the best growth outlooks in the sector, and it keeps an Outperform rating on the stock. |
|
| 07:05 EDT |  | COV | Covidien approves separation of Pharma business, declares Mallinckrodt dividend
Covidien announced that its board of directors has approved the separation of the Pharmaceuticals business from the rest of Covidien. For every eight ordinary shares of Covidien held, Covidien shareholders will receive one ordinary share of Mallinckrodt plc. No fractional shares of Mallinckrodt will be issued. Shareholders will receive cash in lieu of fractional shares. The distribution is expected to occur on June 28, to Covidien shareholders of record as of the close of business on June 19. After the distribution, Mallinckrodt will be an independent publicly traded company and Covidien will retain no ownership interest in Mallinckrodt. Mallinckrodt ordinary shares are expected to begin “regular way” trading on July 1, on the New York Stock Exchange under the ticker symbol "MNK." Covidien will continue to trade on the NYSE under the ticker symbol "COV." Covidien currently expects that “when-issued” trading for both Mallinckrodt and Covidien on the NYSE will begin on June 17. |
|
| 07:01 EDT | | COV | Covidien approves separation of Pharma business, declares Mallinckrodt dividend
|
|
| 06:28 EDT | | JNJ | Johnson & Johnson price target raised to $94 from $88 at Leerink
 Subscribe for More Information |
|
| May 23, 2013 |
| 10:08 EDT |  | JNJ | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:31 EDT | | JNJ | Janssen expects to have more than 25 brand line extensions by 2017
Subscribe for More Information |
|
| 06:29 EDT | | JNJ | Johnson & Johnson coverage assumed with an Underperform at Credit Suisse
Subscribe for More Information |
|
| 05:44 EDT | | STJ | St. Jude Medical study of EnligHTN shows sustained blood pressure reduction
St. Jude Medical announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. Patients enrolled in the EnligHTN I trial had an average blood pressure of 176 / 96 mmHg and patients were drug-resistant, meaning their blood pressure could not be controlled through medication. At one year, patients treated with the EnligHTN Renal Denervation System experienced an average systolic blood pressure reduction of 27 mmHg points when measured in an office setting. |
|
| May 22, 2013 |
| 16:00 EDT |  | JNJ | Options Update; May 22, 2013
Subscribe for More Information |
|
| 07:48 EDT |  | NUVA, SYK | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
Subscribe for More Information |
| |
| 07:00 EDT | | COV | Covidien announces positive results from clinical trial on endoscopic therapy
Subscribe for More Information |
|
| May 21, 2013 |
| 10:46 EDT | | EW | Edwards Lifesciences announces positive outcomes from study of SAPIEN XT
Subscribe for More Information |
|
| 09:09 EDT | | BAX | Baxter granted authorization by European Commission for use of HyQvia
Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014. |
|
| 07:24 EDT | | JNJ | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 15:53 EDT | | NUVA | NuVasive removed from Best Ideas List at Barrington
Barrington removed NuVasive from its Best Ideas List due to recent outperformance but reiterates its Outperform rating. |
|
| 12:20 EDT | | A | Options with decreasing implied volatility: RFMD TTWO LO DDS A
|
|
| 11:12 EDT | | STJ | St. Jude Medical to evaluate defibrilator lead related to reported death
Subscribe for More Information |
|
| 08:05 EDT | | COV | Covidien receives FDA 510(k) clearance for Nellcor pulse oximetry motion claims
Subscribe for More Information |
|
| 06:01 EDT | | AFFX | Affymetrix CFO Tim Barabe to retire from company effective June 28.
Subscribe for More Information |
|
| May 17, 2013 |
| 11:59 EDT | | A | Options with decreasing implied volatility: ILMN LO A HES INFY CSCO
|
| |
|
|
|
|
